Considering the immunosuppressive nature of TGF-β, we undertook a series of studies to investigate the feasibility of targeting the STEAP2 prostate antigen with CAR-Ts that were armored to withstand the TGF-β–rich immunosuppressive environment found in prostate tumors. Here, STEAP2 is linked to prostate neoplasm.